• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

DF/HCC News

    Ibrutinib Combined with FCR—an Aggressive Approach in Younger Patients with CLL

    January 2015 | eNews

    Patients with chronic lymphocytic leukemia (CLL) can live for several years—on average, over half of patients are alive five years after diagnosis

    DF/HCC Members Awarded New or Competitively Renewed Federal Funding

    January 2015 | eNews

    The NIH continues to recognize DF/HCC as a leader in cancer research by awarding funding to a number of our research initiatives

    Imaging Probes Improve Gastrointestinal Cancer Detection

    January 2015 | eNews

    Umar Mahmood, MD, PhD (MGH), a radiologist, and Andrew Chan, MD, MPH (MGH), a gastroenterologist, have worked in both colon cancer and esophageal cancer models to improve dysplasia and cancer detection

    Gastrointestinal Malignancies Research Both Broad and Deep

    January 2015 | eNews

    Gastrointestinal (GI) cancers account for only one-fourth of new cancer diagnoses in the United States but about one-third of cancer deaths annually

    DF/HCC Ranks Among Nation’s Best in the 2014 Cancer Awareness Advertising Awards Program

    January 12, 2015

    Dana-Farber/Harvard Cancer Center was recognized for excellence in the 2014 Cancer Awareness Advertising Awards (CAA Awards) program for its advertising and marketing efforts in the area of faith-based disparities, which scored among the best in the nation

    Pathology Specimen Locator Core Facility

    January 2015 | eNews

    The DF/HCC Pathology Specimen Locator Core facilitates member access to tissue used in research. The Core enables more investigators to access tissues with fewer barriers, achieved through a web-based, integrated network of distributed, searchable databases that contain de-identified, coded, pathologic information on post-diagnostic, excess human materials (including frozen or paraffin-embedded tissues)

    Tumor Imaging Metrics Core

    January 2015 | eNews

    The DF/HCC Tumor Imaging Metrics Core provides standardized, consistent, longitudinal, and multimodality radiological measurements to evaluate therapeutic response for patients enrolled in DF/HCC clinical trials

Displaying results 1 to 7 out of 223
<< First < Previous 1-7 8-14 15-21 22-28 29-35 36-42 43-49 Next > Last >>